PMC9393658_01
Indirect immunofluorescence image of serum from the patient. The following can be
observed: nuclear dots in interphase with typical mitoses in a centromere pattern
(arrows) overlapping with a finely speckled pattern and nucleolar dots with weak
cytoplasmic fluorescence due to the presence of ATA (asterisks).
10.1177_03946320221115310-fig1.jpg
PMC9393658_01_10.1177_03946320221115310-fig1.jpg
fig1-03946320221115310
IIF performed revealed that ACA pattern was overlapping with a nucleolar pattern compatible with ATA (Figure 1).
Sequential plot of the clinical and immunological results, the functional lung tests
and the treatment of the patient. ANA; antinuclear antibodies, ACA; anti-centromere
antibodies, ATA; anti-topoisomerase I antibodies, HRCT; high-resolution computed
tomography, LcSSc: limited cutaneous systemic sclerosis, FVC; forced vital capacity,
DLCO; diffusing capacity of the lungs for carbon monoxide.
10.1177_03946320221115310-fig2.jpg
PMC9393658_01_10.1177_03946320221115310-fig2.jpg
fig2-03946320221115310
Figure 2 shows the sequential plot.
Graph of the lung function parameters. FVC: forced vital capacity, DLCO: diffusing
capacity of the lungs for carbon monoxide.
10.1177_03946320221115310-fig3.jpg
PMC9393658_01_10.1177_03946320221115310-fig3.jpg
fig3-03946320221115310
February 2022, the patient had dyspnoea mMRC 2 (lung function tests: FVC 79%, FEV1 78%, DLCO 48% and KCO 77%), persistent cyanosis without digital ulcers and no synovitis. Figure 3 shows a graph of the lung function parameters.